Navigation Links
Orexigen(R) Therapeutics Appoints Wendy Dixon, Ph.D. to Board of Directors
Date:4/21/2010

o the risk and uncertainties inherent in the Orexigen business, including, without limitation: additional analyses of data from the Contrave Phase 3 trials and any other clinical trials of Contrave may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted clinical trials; the FDA may not agree with the Company's interpretation of efficacy and safety results; the FDA may require Orexigen to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of NDA for Contrave; the third parties on whom Orexigen relies to assist with the development programs for Contrave, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. All conclusions and determinations contained herein are subject to the Company's further analysis of the clinical data. The ultimate determination of the safety and efficacy of Contrave will be made by the FDA and other relevant regulatory authorities.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
10. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... 23, 2015   Leatt Corporation  (OTCQB: LEAT), a global ... all forms of sports, including extreme motor sports, and ... today that the UISP Lega Motociclismo Lombardia, an Italian ... to wear a neck brace during its racing competitions.  ...
(Date:1/23/2015)... (NYSE: MNK ) announced today that its ... The open-ended authorization permits the company to repurchase up ... "Funding additional initiatives and seeking attractive business ... pursue a range of focused growth strategies," said ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... NEWTON, Mass. , Aug. 5 Microfluidics International Corporation (OTC Bulletin Board: ... on Tuesday, August 10, 2010 , at 8:30am ET . , ... (Logo: http://photos.prnewswire.com/prnh/20090811/NE59652LOGO ) , , ... ) , , , ...
... 5 Cornerstone Therapeutics Inc. (Nasdaq: ... specialty pharmaceutical company focused on acquiring, developing and commercializing ... today announced that its product candidate CRTX-067 is an ... mg hydrocodone polistirex suspension product that will be a ...
Cached Medicine Technology:Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010 2Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010 3Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010 4Cornerstone Therapeutics Announces Development of Generic for Tussionex® 2Cornerstone Therapeutics Announces Development of Generic for Tussionex® 3
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, ... dresses. View website of AngelWeddingDress.com to find ... wedding dresses online for a bridal party. AngelWeddingDress offers ... for them. Its maternity wedding dresses are specially designed ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved ... upcoming 32nd Annual Miami Breast Cancer Conference ... LLC (PER®) , shares that “a fast-growing, virulent” cancer ... she had not followed up her clean mammogram with ...
(Date:1/22/2015)... 22, 2015 IsoComforter, Inc. has introduced the ... patented IsoTube design to treat specific body parts and muscle ... progressive and easy to use patented cold therapy machine with ... related orthopedic and muscle injuries. IsoComforter has become the ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... , , PHOENIX, Aug. 14 ... largest group of medical professionals in Arizona devoted exclusively to cancer ... facility in Phoenix last week. Located at 1916 W. Bethany Home ... to advanced therapies and leading edge technology. The facility marks ...
... Mich., Aug. 14 Work and economy related stress is taking ... independent survey conducted by American Laser Centers, the largest provider of ... respondents who took part in the survey (47 percent) currently feel ... , , The physical toll of their ...
... , , INDIANAPOLIS, Aug. ... regulations taking effect today, Stericycle ExpertRECALL has introduced a CPSIA ... new rules. , , , , ... Safety Commission as they safeguard consumers against harmful products," said ...
... , NOVATO, Calif., Aug. 14 Purple Communications, Inc. ... text relay services, and professional interpreting for deaf, hard of hearing, ... ended June 30, 2009. On August 13, 2009, the Company filed ... Form 10-Q for the quarter ended June 30, 2009. , ...
... , , SAN FRANCISCO, Aug. ... few have success rates higher than 50 percent and none have been ... r al H e alth International (NHI), ... today, its Femmenessence line has been clinically proven to alleviate ...
... , , MOUNTAIN VIEW, ... enables the North American home healthcare and disease management markets ... the traditionally mature patient monitoring space. The single largest factor ... incidence of cardiovascular disease (CD) in the U.S. This trend ...
Cached Medicine News:Health News:Arizona Oncology Opens Radiation Facility at Phoenix Baptist Hospital 2Health News:Arizona Oncology Opens Radiation Facility at Phoenix Baptist Hospital 3Health News:New Consumer Safety Regulations Impose Additional Recall Requirements on Manufacturers and Retailers 2Health News:Purple Communications(TM) Announces Second Quarter 2009 Results 2Health News:Purple Communications(TM) Announces Second Quarter 2009 Results 3Health News:Purple Communications(TM) Announces Second Quarter 2009 Results 4Health News:Purple Communications(TM) Announces Second Quarter 2009 Results 5Health News:Purple Communications(TM) Announces Second Quarter 2009 Results 6Health News:Purple Communications(TM) Announces Second Quarter 2009 Results 7Health News:Purple Communications(TM) Announces Second Quarter 2009 Results 8Health News:When it Comes to Natural Remedies for Hormonal Balance, the Proof is in the Clinical Research 2Health News:Smart Payment Strategies Enable Growth in Home Health Care and Disease Management Markets for Remote Patient Monitoring, Finds Frost & Sullivan 2Health News:Smart Payment Strategies Enable Growth in Home Health Care and Disease Management Markets for Remote Patient Monitoring, Finds Frost & Sullivan 3Health News:Smart Payment Strategies Enable Growth in Home Health Care and Disease Management Markets for Remote Patient Monitoring, Finds Frost & Sullivan 4
Inquire...
One Pair of Knife Raising Blocks to move blade up 1 inch for adpatation of a freezing stage....
Supercassette quick release holder for the 8000 Series sliding microtome to allow for the use of wax supercassettes, 75x52x19 mm....
Steel Knife with Box for the Series 8000 Sliding Microtome. D-Profile, 240 x 33 x 13mm. 22 Degree angle, tapped to accept holder for Shandon knife sharpener....
Medicine Products: